The U.S. Patent and Trademark Office (USPTO) is seeking an early resolution in a dispute over patent extension with Danish pharmaceutical manufacturer H. Lundbeck A/S. Currently under deliberation in Virginia’s federal court, Lundbeck’s appeal pertains to prolonging the term of a patent associated with a drug addressing Post-Traumatic Stress Disorder (PTSD) by three months.
Presenting their case before the court, the USPTO deemed the situation as clear-cut and hence achievable of an expedited conclusion. Lundbeck’s bid for extending the patent’s lifespan is currently awaiting a determination. Continued deliberations in court are expected to shape the future trajectory of this singular patent dispute.